Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics
Dr. Reddy's Laboratories Ltd (RDY)
Today's Latest Price: $71.06 USD
Updated Jan 15 7:00pm
Add RDY to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
RDY Stock Summary
- The price/operating cash flow metric for Dr Reddys Laboratories Ltd is higher than just 2.3% of stocks in our set with a positive cash flow.
- With a year-over-year growth in debt of -41.16%, Dr Reddys Laboratories Ltd's debt growth rate surpasses only 7.68% of about US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for RDY comes in at 196.81% -- higher than that of 98.39% of stocks in our set.
- Stocks that are quantitatively similar to RDY, based on their financial statements, market capitalization, and price volatility, are AGCO, ITT, BRKR, FINV, and VAR.
- RDY's SEC filings can be seen here. And to visit Dr Reddys Laboratories Ltd's official web site, go to www.drreddys.com.
RDY Stock Price Chart Interactive Chart >
RDY Price/Volume Stats
| Current price | $71.06 | 52-week high | $73.50 |
| Prev. close | $72.01 | 52-week low | $33.33 |
| Day low | $70.60 | Volume | 164,000 |
| Day high | $71.44 | Avg. volume | 172,500 |
| 50-day MA | $67.80 | Dividend yield | 0.38% |
| 200-day MA | $60.03 | Market Cap | 11.78B |
Dr. Reddy's Laboratories Ltd (RDY) Company Bio
Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.
RDY Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $71.06 | $2080.28 | 2789% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dr Reddys Laboratories Ltd. To summarize, we found that Dr Reddys Laboratories Ltd ranked in the 93th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 2803.17% on a DCF basis. The most interesting components of our discounted cash flow analysis for Dr Reddys Laboratories Ltd ended up being:
- The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately only 11.39% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- Dr Reddys Laboratories Ltd's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
- The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than merely 0% of stocks in its sector (Healthcare).
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 2732% |
| 1% | 2761% |
| 2% | 2789% |
| 3% | 2817% |
| 4% | 2846% |
| 5% | 2874% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as RDY, try BEAT, OMI, CORT, FVE, and ALPN.
Loading social stream, please wait...